Compare GSK plc (GSK) vs 3M Company (MMM) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

3M (MMM) trades at $162.41, up 3.7% on the day, with a bullish technical signal supported by moving averages and strong recent earnings beats. The stock shows robust profitability with a 39.71% gross margin and 72.14% ROE, though valuation ratios like P/E of 30.93 appear elevated. Recent news highlights demand for safety products from wildfire smoke and a new Airbus supply agreement, while Q2 2026 earnings are anticipated at $2.27 EPS on July 21.

Outlook is cautiously optimistic with analyst consensus at Buy (45%) and a $143 price target below current levels, indicating limited upside. Risks include consumer segment weakness and high debt, but cost optimization and diversified operations provide stability. The stock's momentum depends on continued earnings delivery and macroeconomic conditions.